olmesartan medoxomil

Also found in: Dictionary.

olmesartan medoxomil

Benicar, Olmetec (UK)

Pharmacologic class: Angiotensin II type 1-receptor antagonist

Therapeutic class: Antihypertensive

Pregnancy risk category C (first trimester), D (second and third trimesters)

FDA Box Warning

• When used during second or third trimester of pregnancy, drug may cause fetal harm or death. Discontinue as soon as possible when pregnancy is detected.


Selectively blocks binding of angiotensin II to specific tissue receptors in vascular smooth muscle and adrenal gland. This action blocks vasoconstrictive effects of renin-angiotensin system as well as aldosterone release, thereby reducing blood pressure and possibly preventing vascular remodeling related to arteriosclerosis.


Tablets: 5 mg, 20 mg, 40 mg

Indications and dosages


Adults and children ages 6 to 16 weighing more than 35 kg (77 lb): 20 mg P.O. once daily; may titrate to 40 mg daily after 2 weeks, if needed

Children ages 6 to 16 weighing 20 kg (44 lb) to less than 35 kg (77 lb): 10 mg P.O. daily; may titrate to 20 mg daily after 2 weeks, if needed.

Dosage adjustment

• Volume depletion


• Hypersensitivity to drug or its components


Use cautiously in:

• hepatic disease, renal dysfunction, hypovolemia, sodium depletion

• elderly patients

• pregnant patients (first trimester; not recommended in second and third trimesters)

• breastfeeding patients

• children (safety and efficacy not established).


• Give with or without food.

• Know that drug may be used alone or with other antihypertensives.

Adverse reactions

CNS: fatigue, dizziness, headache, insomnia

CV: orthostatic hypotension, chest pain, peripheral edema, syncope, tachycardia

EENT: sinusitis, rhinitis, pharyngitis

GI: nausea, diarrhea, constipation, abdominal pain, dry mouth

GU: hematuria

Hematologic: hyperglycemia

Musculoskeletal: back pain, arthritis, muscle weakness

Respiratory: upper respiratory infection symptoms, bronchitis, cough

Skin: dry skin, rash, inflammation, pruritus, alopecia, angioedema

Other: dental pain, flulike symptoms


Drug-diagnostic tests. Triglycerides: increased level

Drug-herbs. Ephedra (ma huang): antagonism of antihypertensive effect

Patient monitoring

• Monitor vital signs and cardiovascular status. Stay alert for orthostatic hypotension, syncope, and peripheral edema.

• Check temperature and watch for signs and symptoms of flu and other infections (especially respiratory and EENT infections).

• Watch for angioedema.

• In volume-depleted patient, monitor blood pressure carefully after initial dose. Transient blood pressure drop may occur.

Patient teaching

• Tell patient to take at same time each day, with or without food.

• Advise patient to promptly report signs and symptoms of infection, particularly respiratory symptoms.

• Inform patient that when he begins therapy, inadequate fluid intake, excessive perspiration, vomiting, or diarrhea may cause blood pressure to drop. Tell him to change position slowly to avoid dizziness or fainting.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.

Tell female patient to notify pre-scriber immediately if she suspects pregnancy.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the tests and herbs mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved


An angiotensin-II receptor blocker used as a monotherapy or with other agents to manage hypertension.
Adverse effects
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

olmesartan medoxomil

A selective angiotensin II receptor antagonist drug used to treat high blood pressure. The drug is effective on a once-a-day dosage. It is a prodrug that is converted to olmesartan by esterases present in the intestine and portal vein blood.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
2 medicines have passed Consistency Evaluation: Olmesartan Medoxomil Tablet and Fudosteine tablets, and 2 more have obtained clinical approvals.
Indian multinational drug firm Alembic Pharmaceuticals (NSE: APLLTD) has received approval from the US health regulator for its generic Olmesartan Medoxomil and Amlodipine tablets, the company reported on Tuesday.
Mumbai, India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has received final approval from the US Food and Drug Administration (FDA) for its Olmesartan Medoxomil Tablets, a blood pressure treatment, the company reported on Friday.
Amlodipine + Olmesartan Medoxomil Tablets is part of an ever growing portfolio of products that Ajanta has developed for the US market.
FDA approves label changes to include intestinal problems (sprue-like enteropathy) linked to blood pressure medicine olmesartan medoxomil. US Food and Drug Administration Web site.
Hence, the objective of the present work was to formulate the liquisolid compacts for olmesartan medoxomil to improve the solubility and dissolution rate, which can increase clinical efficacy or reduce the oral dosage required to achieve the same effect.
It combines olmesartan medoxomil (which blocks angiotensin II receptors), amlodipine (which inhibits the entrance of calcium into the blood vessel walls), and hydrochlorothiazide (a diuretic which reduces water volume in the blood).
Tribenzor combines amlodipine, marketed by Pfizer as Norvasc, olmesartan medoxomil, marketed by Daiichi Sankyo as Benicar, and a third drug, hydrochlorothiazide.
The aggressive use of statins and other medications is critical in helping to reverse atherosclerosis (the angiotensin receptor blocker olmesartan medoxomil [Benicar] may be effective in reversing vascular damage in patients with high blood pressure, according to a study reported in the June Journal of the American Society of Hypertension).
Eight (7.3%) drugs were registered to treat cardiovascular conditions: bosentan (C02KX01), barnidipine (C08CA12), midodrine (C01CA17), dofetilide (C01BD04), ezetimibe (C10AX09), levosimendan (C01CX08), olmesartan medoxomil (C09CA08), and rosuvastatin (C10AA07).
Elsewhere in the regional list, drug group GlaxoSmithKline said it had entered into an agreement with Japanese company Daiichi Sankyo to sell its hypertension drug Olmesartan Medoxomil in India.